Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment

BACKGROUND: Inotuzumab Ozogamicin (INO), has demonstrated an improvement in overall survival, high rate of complete remission, favorable patient‐reported outcomes, and manageable safety profile vs standard of care (SoC; intensive chemotherapy) for relapsed/refractory (R/R) acute lymphoblastic leukem...

Descripción completa

Detalles Bibliográficos
Autores principales: Marks, David I., van Oostrum, Ilse, Mueller, Sabrina, Welch, Verna, Vandendries, Erik, Loberiza, Fausto R., Böhme, Sarah, Su, Yun, Stelljes, Matthias, Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792500/
https://www.ncbi.nlm.nih.gov/pubmed/31436395
http://dx.doi.org/10.1002/cam4.2480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792500/
https://www.ncbi.nlm.nih.gov/pubmed/31436395
http://dx.doi.org/10.1002/cam4.2480

Ejemplares similares